Opendata, web and dolomites

FIDA SIGNED

Scale-up of our disruptive antibody analytical platform based in flow-induced dispersion analysis (FIDA) to increase efficiency in the research of new antibodies and vaccines

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "FIDA" data sheet

The following table provides information about the project.

Coordinator
FIDA-TECH APS 

Organization address
address: TONSBERGVEJ 49 HIMMELEV
city: ROSKILDE
postcode: 4000
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Total cost 3˙451˙604 €
 EC max contribution 2˙603˙936 € (75%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-EIC-FTI-2018-2020
 Funding Scheme IA
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2021-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FIDA-TECH APS DK (ROSKILDE) coordinator 1˙394˙621.00
2    FACHHOCHSCHULE NORDWESTSCHWEIZ CH (WINDISCH) participant 626˙043.00
3    ELVESYS FR (PARIS) participant 340˙105.00
4    NOVOPTIM SARL FR (PARIS) participant 243˙166.00

Map

 Project objective

Therapeutic antibodies have rapidly become a major component of modern medicine. The global research antibodies market size is expected to reach €3.8bn by 2025. However, exiting research tools have not been able to eliminate Hyper-Sensitivity Reactions (HSRs) against the biologic drug by the patient’s immune system. HSRs are estimated to occur in 10-15% of hospital patients and can arise for any biologic, mostly antibodies. Antibodies are also important in the R&D of new vaccines. To test vaccines, it is necessary to follow the generation of auto-antibodies to verify that the vaccine is working well. This analysis is done with the same tools used in the antibodies research, and with the same drawbacks: artificial assays based on non-native sample materials. Vaccine R&D is immensely costly: up to €400m over a 11-year timeline is standard for a completely new vaccine and overall failure rate from preclinical through to registration is 94%. FIDA is a patented solution that simplifies and standardises immunological measurements under native conditions. We go from 15 treatment steps on current platforms to a single step with FIDA. FIDA is a powerful methodology for quantifying and characterising antibodies and antibody binding with up to 10-times higher sensitivity than present tools. Assays take 5-20 minutes to run, 90% less than alternatives, with full walk-away automation as-standard. FIDA’s simplicity allows to set-up assays versus new targets within 1 day versus 10 days with current tools. It is based on a microcapillary system that needs <3μl of sample, 16-times less than today’s methods to support parallel testing of multiple early-pipeline drug samples. FIDA uses up to 10μl of standard reagents and running costs are €2.60/assay, saving 61% in operational costs. FIDA focuses on both the global research antibodies market and vaccine R&D market at pre-clinical phase (in which certification as a diagnostic/prognostic device is not needed).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FIDA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FIDA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.1.)

GoSafe (2019)

Restoring complete sensory ability for natural walking of amputees

Read More  

BIOSNAP (2019)

SMART, SUSTAINABLE & CONVENIENT UNIT DOSE PACKAGING

Read More  

Mag-ID (2019)

Magnetic identification

Read More